< 1 minute read
Dec. 20, 2021
Critical On-Target Toxicity with a VPS34 Kinase Inhibitor?
"compound 5"
oral selective VPS34 kinase inhibitor discontinued due to potential toxicity SBDD and SAR optimization Journal of Medicinal Chemistry Genentech Inc.
Loading...
